A Study to Evaluate the Relative Bioavailability and Effect of Food on Two Formulations of the MK-3682A Fixed-Dose Combination Tablets (MK-3682/MK-5172/MK-8742, 300 mg/ 100 mg/50 mg) in Healthy Adult Subjects. - MK-3682A/PN018

Merck Sharp & Dohme (MSD)0 个研究点目标入组 22 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

暂无简介。

•1. Non-tobacco using males and non-pregnant females, 18-55 years of age, inclusive.
•2. A body mass index (BMI) of 19-32 kg/m² inclusive.
•3. Good health as determined by lack of clinically significant abnormalities in health assessments performed at screening.

•1. Females who are pregnant, lactating or likely to become pregnant during the study.
•2. Significant history or current evidence of chronic infectious disease, system disorders, organ dysfunction, especially cardiovascular disorders.
•3. Receipt of any drug as part of a research study within 30 days before initial dosing.

发起方

Merck Sharp & Dohme (MSD)